Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Samuel Francis Ruder
Observed names:
S. Ruder,
Samuel F. Ruder,
Samuel Ruder
Institutions:
NewYork–Presbyterian Hospital,
Weill Cornell Medicine,
Weill Cornell Medical Center
Observed institutions:
Houston Methodist,
NewYork–Presbyterian Hospital,
Cornell University,
Weill Cornell Medicine,
Tisch Cancer Institute,
Weill Cornell Medical Center,
The University of Texas Health Science Center at Houston,
Icahn School of Medicine at Mount Sinai
show all 8
ORCID:
0000-0003-3676-2798
Observed ORCID:
0000-0003-3676-2798
OpenAlex ID:
A5047424932
Works
18
Awards
1
Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
2019
·
Scot A. Niglio
, Rachel Jia
, et al.
·
European Urology
·
84
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis
2022
·
Samuel Ruder
, Yan Gao
, et al.
·
Human Pathology
·
23
Advances in PSMA-Targeted Radionuclide Therapeutics
2025
·
Samuel Ruder
, Andres Ricaurte-Fajardo
, et al.
·
Current Treatment Options in Oncology
·
9
Cell-surface targets for prostate cancer therapeutics
2026
·
Samuel Ruder
, Pardis Ziaeefar
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
6
Quantification of collagen content and stromal cellularity within reactive stroma is predictive of prostate cancer biochemical recurrence and specific death
2023
·
Yi Ding
, Ping Bu
, et al.
·
Human Pathology
·
6
PDF
Antibody–drug conjugates in urothelial carcinoma: current status and future
2025
·
Samuel Ruder
, Juana Martinez
, et al.
·
Current Opinion in Urology
·
5
Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector.
2024
·
Samuel Francis Ruder
, Michael Philip Sun
, et al.
·
Journal of Clinical Oncology
·
3
PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.
2025
·
Valentina Marulanda Corzo
, Charlene Thomas
, et al.
·
Journal of Clinical Oncology
·
2
Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).
2025
·
Abdul Baseet Arham
, Charlene Thomas
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)
2024
·
Samuel Ruder
, Michael Sun
, et al.
·
Cancer Research
·
1
Hereditary antithrombin deficiency in pregnancy
2026
·
Oluwatosin Afolabi
, Samuel Ruder
, et al.
·
British Journal of Haematology
Abstract LB472: Theranostic 89Zr/225Ac anti-CEACAM5 radioimmunotherapy for metastatic castration-resistant prostate cancer
2026
·
Ambika Parmar
, Samuel F. Ruder
, et al.
·
Cancer Research
Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.
2026
·
Abdul Baseet Arham
, Escarleth Fernandez
, et al.
·
Journal of Clinical Oncology
PDF
795 Expression of CEACAM5 and TROP2 in Advanced Prostate Cancer: Heterogeneity and Correlation with Morphologic and Immunophenotypic Subtypes
2026
·
Jesus Delgado-de la Mora
, Eda Nur Kozan
, et al.
·
Laboratory Investigation
PDF
Revolucionando el tratamiento del cáncer de próstata: la terapia dirigida al antígeno prostático específico en el enfoque moderno terapéutico
2025
·
A. Ricaurte Fajardo
, V. Marulanda Corzo
, et al.
·
Revista Española de Medicina Nuclear e Imagen Molecular
PD13-06 225Ac-J591 PSMA-TARGETED RADIONUCLIDE THERAPY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH PRIOR 177Lu-PSMA THERAPY
2025
·
Valentina Marulanda-Corzo
, Gabriel Raab
, et al.
·
The Journal of Urology
PDF
Pd13-07 Psma-targeted Actinium-225 Therapy in Metastatic Castration-resistant Prostate Cancer: Comparative Outcomes Between Monotherapy Vs. Combination Therapy
2025
·
Valentina Marulanda-Corzo
, Gabriel Raab
, et al.
·
The Journal of Urology
PDF
Pd01-11 Phase I Dose-escalation Trial of Multiple and Fractionated-dose Psma-targeted Alpha Radionuclide (225ac-j591) for Metastatic Castration-resistant Prostate Cancer
2024
·
Michael Sun
, Jones Nauseef
, et al.
·
The Journal of Urology
PDF
Show more works
View as search
Works count:
18
Citation count:
141
H-index:
5
I10-index:
2
Year
Topic
Type